A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors
暂无分享,去创建一个
A. Groves | I. Kayani | J. Dickson | J. Bomanji | M. Caplin | T. Win | B. Conry
[1] A. Runz,et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[2] J. Tabernero,et al. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. , 2007, Endocrine-related cancer.
[3] R. Baum,et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[4] A. Nicholson,et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease , 2006, Thorax.
[5] T. Meyer,et al. Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients. , 2009, Lung cancer.
[6] G. Rossi,et al. Bronchial typical carcinoid tumors. , 2006, Seminars in thoracic and cardiovascular surgery.
[7] Y. Soini,et al. Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity , 2000, Cancer.
[8] K Schnabel,et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. , 1999, International journal of radiation oncology, biology, physics.
[9] R. Bale,et al. 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007, Journal of Nuclear Medicine.
[10] P C Goodman,et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. , 1998, AJR. American journal of roentgenology.
[11] F. Mottaghy,et al. Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours , 2006, Journal of internal medicine.
[12] J. Charboneau,et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. , 1990, Cancer research.
[13] P. Schöffski,et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data , 2001, European Journal of Nuclear Medicine.
[14] E. Krenning,et al. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[15] R. Rosell,et al. PET/CT fusion scan in lung cancer: current recommendations and innovations. , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[16] V. Lowe,et al. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. , 2007, Chest.
[17] J. Choi,et al. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. , 2007, AJR. American journal of roentgenology.
[18] P. Gattuso,et al. Well-differentiated neuroendocrine carcinomas: the spectrum of histologic subtypes and various clinical behaviors. , 2006, Seminars in thoracic and cardiovascular surgery.
[19] W. Travis,et al. The new World Health Organization classification of lung tumours , 2001, European Respiratory Journal.
[20] Giovanni Paganelli,et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] M. Chung,et al. Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.
[22] A. Groves,et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐DPhe1,Tyr3‐octreotate) and 18F‐FDG , 2008, Cancer.